Advice

following a full submission:

ocrelizumab (Ocrevus®) is not recommended for use within NHS Scotland.

Indication under review: The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Two phase III studies identified superiority of ocrelizumab when compared with another disease modifying treatment in adult patients with relapsing forms of multiple sclerosis.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Download full details234KB (PDF)

Download

Medicine details

Medicine name:
ocrelizumab (Ocrevus)
SMC ID:
1344/18
Indication:
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Not recommended
Date advice published:
09 July 2018